Improved sleep efficiency is associated with reduced cardio-metabolic risk: Findings from the MODERN trial.

Abstract

Poor sleep increases cardio-metabolic risk, but limited information on the impact of sleep for the improvement of cardio-metabolic health exists. This analysis examined the impact of sleep on a health and lifestyle modification programme to reduce cardio-metabolic disease risk factors. Secondary analysis of the MODERN randomised controlled trial to reduce cardio-metabolic risk was undertaken at baseline and 24-month follow-up. Participants aged 40-70\xa0years (n\xa0=\xa0121) with three or more cardio-metabolic risk factors were randomised to a health and lifestyle modification intervention (n\xa0=\xa059) or usual care (n\xa0=\xa062), and underwent 7\xa0day/night actigraphy to assess total sleep time, sleep efficiency (%), number of awakenings/night and physical activity levels. Blood pressure, blood lipid and glycaemic levels, anthropometric and diet measures were collected. The mean age was 59\xa0±\xa07\xa0years and 37% were male. Baseline sleep measures were not different between groups. At the 24-month follow-up, both groups showed improvements in cardio-metabolic risk factors, albeit the change in blood pressure was greater in the intervention compared with the usual care group (systolic blood pressure: -11 versus -4\xa0mmHg, p\xa0=\xa0.014). There were no differences between groups for diet, physical activity or sleep parameters. An increase in sleep efficiency was independently associated with lower systolic blood pressure (β\xa0=\xa0-2.117, p\xa0=\xa0.002) and higher high-density lipoprotein levels (β\xa0=\xa00.040, p\xa0=\xa0.033); an increase in total sleep time was associated with lower low-density lipoprotein levels (β\xa0=\xa0-0.003, p\xa0=\xa0.038) at 24\xa0months. Overall, improvement in sleep quality over time was beneficial to reduce blood pressure and lipid levels. These findings highlight sleep as a potential target to reduce cardio-metabolic risk.